Rosen Law Firm has initiated a class action lawsuit against uniQure N.V., targeting investors who acquired shares during a specific trading window between September 24 and October 31, 2025. The litigation alleges that company executives made material misrepresentations regarding the FDA approval status of the Pivotal Study design for their Huntington's Disease therapeutic candidate and allegedly downplayed the probability of timeline delays affecting their Biologics License Application submission.
The case centers on assertions that uniQure failed to accurately communicate regulatory risks and development timelines to shareholders during the specified period. Investors seeking to participate in the action as lead plaintiff must submit their applications by April 13, 2026, establishing a critical filing deadline for affected shareholders.
Affected investors are encouraged to consult with securities counsel to evaluate their eligibility and understand the litigation process. The lead plaintiff role carries distinct responsibilities and may influence case strategy and settlement negotiations.